FIELD: biotechnology.
SUBSTANCE: human antibody is disclosed, that binds specifically to the human OX40. Preferably, the antibody has high affinity with respect to OX40 receptor and activates the receptor in vitro and in vivo. The antibody may be a full length antibody or its antigen-binding part. The nucleic acids are presented, vectors and host cells for expression of recombinant human antibodies, and also the methods of synthesis of recombinant human antibodies are proposed.
EFFECT: invention is used for modulating the activity of receptor, eg the human suffering from a disorder in which the activity of OX40 is detrimental.
12 cl, 53 dwg, 1 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES AGAINST OX40 AND THEIR USE | 2017 |
|
RU2783314C2 |
| HUMANISED ANTIBODIES TO OX40 AND METHODS FOR USE THEREOF | 2015 |
|
RU2709742C2 |
| ANTI-OX40 ANTIBODIES AND THEIR APPLICATION | 2017 |
|
RU2753493C2 |
| ANTI-HLA-A2 ANTIBODIES AND THEIR APPLICATION METHODS | 2018 |
|
RU2782276C2 |
| METHODS FOR IDENTIFICATION, SELECTION, ENRICHMENT AND DEPLETION OF Tr1 CELLS POPULATIONS, Tr1 CELLS POPULATIONS, PHARMACEUTICAL COMPOSITIONS, METHODS FOR THERAPY EFFECT MONITORING | 2011 |
|
RU2627445C2 |
| ANTIBODIES, THEIR APPLICATION AND METHODS OF APPLICATION | 2016 |
|
RU2725221C2 |
| NEW ANTI-HLA-A2 ANTIBODIES AND THEIR APPLICATION | 2018 |
|
RU2805674C2 |
| ANTIBODY MOLECULES THAT BIND CD137 AND OX40 | 2019 |
|
RU2817602C2 |
| CANCER TREATMENT USING CHIMERIC ANTIGEN-SPECIFIC RECEPTOR BASED ON HUMANISED ANTI-EGFRvIII ANTIBODY | 2014 |
|
RU2708032C2 |
| CANCER TREATMENT WITH CHIMERIC CD33 ANTIGEN RECEPTOR | 2015 |
|
RU2747384C2 |
